Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.

Thomas MartinAmrita KrishnanKwee YongKatja WeiselManeesha MehraSandhya NairKeqin QiAnil LondheJoris DielsConcetta CriveraCarolyn C JacksonYunsi OlyslagerMartin VogelJordan M SchecterArnob BanerjeeSatish ValluriSaad Z UsmaniJesus G BerdejaSundar Jagannath

Published in: EJHaem (2021)

Cilta-cel demonstrated significantly superior effectiveness over PCT for all outcomes, highlighting its potential as an effective therapy in patients with triple-class exposed RRMM.

Keyphrases

multiple myeloma
healthcare
public health
randomized controlled trial
emergency department
systematic review
primary care
mental health
acute myeloid leukemia
acute lymphoblastic leukemia
metabolic syndrome
health information
mesenchymal stem cells
climate change
insulin resistance
glycemic control